The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1235
May 22, 2006
View Complete Issue         Table of Contents 2019 
Anidulafungin (Eraxis) for Candida Infections
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Anidulafungin (Eraxis) for Candida Infections
May 22, 2006 (Issue: 1235)
Anidulafungin (ay nid yoo la fun jin; Eraxis - Pfizer), a third intravenous echinocandin antifungal, has been approved by the FDA for treatment of esophageal candidiasis, candidemia, and other complicated Candida infections (intra-abdominal abscess...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Anidulafungin (Eraxis) for Candida Infections
Article code: 1235b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.